However, the efficacy of SCFA in IBD patients has been brought into question due to the reduced responsiveness of their peripheral blood mononuclear cells to n-butyrate following toll-like receptor-2 (TLR-2) activation (132). Here, TLR2 is linked to inflammatory bowel disease.